Research Chemical Designation & Liability

Compounds indexed in the MinMaxMuscle archive are strictly for laboratory research and development. They are NOT approved for human consumption. Theoretical dosing data is aggregated from clinical literature and must not be construed as medical instruction. Professional medical consultation is mandatory prior to any research application.

Full Disclaimer
Archive Identifier

Pegbelfermin

Metabolic & Weight Loss

Molecular Dossier

  • Rank Index: 48
  • Status: Phase 2 Clinical
  • What does this mean?
  • Molecular Structure: MW: ~42 kDa (FGF-21 + PEG) | PEGylated protein analogue

About Pegbelfermin

Pegbelfermin (BeiGene, formerly Intercept) is a PEGylated FGF-21 analogue designed for sustained hepatic signaling. Phase 2b trials in MASH patients showed liver fat reduction and improvement in fibrosis markers. Unlike efruxifermin (Roche's fatty-acid conjugate), pegbelfermin uses polyethylene glycol conjugation for half-life extension. Phase 2 trials in alcoholic liver disease (ALD) and NASH are ongoing as of May 2026. Once-weekly or every-two-weeks subcutaneous injection. The FGF-21 mechanism is particularly attractive for MASH because it activates PPARγ-like signaling, improving adiponectin and reducing hepatic inflammation without appetite suppression.

Clinical Focus

PEG-Conjugated FGF-21 — Liver-Targeted Metabolic Therapy

Archival Aliases

BEI011, FGF-21-PEG, Intercept FGF-21

Frequently Asked Questions

Clinical Data Matrix

Parameter Clinical Value
Molecular Weight MW: ~42 kDa (FGF-21 + PEG) | PEGylated protein analogue
Primary Pathway Metabolic & Weight Loss
Research Phase Phase 2 Clinical

Clinical Pros

  • Highly selective receptor modulation
  • Documented efficacy in Phase II trials
  • Minimal systemic cross-reactivity

Research Limitations

  • Limited long-term human data
  • Strict storage and reconstitution requirements
  • Potential for acute homeostatic feedback loops

Community Discussion

Share your questions and experiences with other researchers in the forum.

Discuss in Forum

Clinical Reference Nodes

[REF 1] pubmed.ncbi.nlm.nih.gov
[REF 2] clinicaltrials.gov

Data Verified: 2026-05-07

Synergistic Matrix